AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06485856 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Description: Evaluation of the pain level of patients who are followed in intensive care and cannot speak during the procedural procedure with 3 different methods.
Study NCT06232603 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education of medication management
Description: Video and handout materials will be provided
Study NCT06299410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284 10 mg
Description: ITI-1284 tablet
Study NCT06299410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284 20 mg
Description: ITI-1284 tablet
Study NCT05523206 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05083780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorphenesin Carbamate, Hydroxychloroquine
Description: In addition to the mFOLFIRINOX therapy(backbone therapy), chlorphenesin carbamate 250 mg, and hydroxychloroquine 200 mg will be administered orally twice daily for up to 48 weeks.
Study NCT06216886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 UNT [Botox]
Description: Intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of onabotA. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
Study NCT06216886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% for Injection, Preservative Free
Description: intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of saline. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
Study NCT06318520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Calcium silicate based resin cement and resin modified glass ionomer cement
Description: Investigators will restore MIH teeth with stainless steel crowns using calcium silicate-based resin cement and resin-modified glass ionomer cement and evaluate their 1-year success.
Study NCT05452460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Description: The mindfulness program called Mindfulness-based peak performance (MBPP) will be used in this study. MBPP is a program that consists of eight 60-min training, and a 60-min session weekly for 8-weeks. The MBPP program will include (1) 5 minutes of will start with a brief recap of the preceding session and homework discussion, (2) after which the 5 minutes of a brief story about performance aimed at inducing the learning motivation of the participants; (3) Followed by 20 minutes of a theoretical lecture introducing a new topic and then (4) 25 minutes of mindfulness exercise. (5) Finally, how to apply the mindfulness skills to sports context will be discussed at the end of each session for 5 minutes.
Study NCT04665739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection
Study NCT04665739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection
Study NCT04665739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04665739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04665739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Given PO
Study NCT04665739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given FDG
Study NCT04665739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fludeoxyglucose F-18
Description: Given FDG
Study NCT04665739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given IV
Study NCT04665739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT04665739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT06232603 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education of medication management
Description: Video and handout materials will be provided
Study NCT06557057 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study NCT05587231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: The experimental group will have the Dextenza Insert implanted immediately after surgery
Study NCT05587231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Fluorometholone
Description: Steroid drops will be administered by the subject according to the standard of care taper
Study NCT04665739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT
Study NCT04665739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT
Study NCT04945707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]
Description: Ferric derisomaltose (Monoferric) 1000 mg X1 (for subject \<50 kg, 20 mg/kg
Study NCT04945707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT05577598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of a DBS therapy system
Description: The system is called Reclaim DBS Therapy for OCD und is marketed by Medtronic (Minneapolis, Minnesota). It has a HDE status by the FDA. The system consists of two quadripolar electrodes (Medtronic Reclaim DBS) as well as a generator (Medtronic Activa PC), which will be implanted into a subcutaneous pocket below the clavicula.
Study NCT04665739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04665739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05577598 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Implantation of a DBS therapy system
Description: The system is called Reclaim DBS Therapy for OCD und is marketed by Medtronic (Minneapolis, Minnesota). It has a HDE status by the FDA. The system consists of two quadripolar electrodes (Medtronic Reclaim DBS) as well as a generator (Medtronic Activa PC), which will be implanted into a subcutaneous pocket below the clavicula.
Study NCT05127473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, placebo
Description: Placebo will be used to dilute the IMP to different Mim8 concentrations
Study NCT06269744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Screening Outreach
Description: Individuals in the interventional arm will receive an information letter, followed by mailed FIT kit. Individuals that do not respond will receive reminder phone calls. Individuals that do respond will receive navigation to assist with completion of FIT and the colonoscopy if FIT is abnormal. Clinic processes will be closely followed and the primary care provider will be informed of the program.
Study NCT05864638 — intervention group
Intervention type: DEVICE
Intervention: Endovascular treatment
Description: Endovascular treatment, such as mechanical thrombectomy with stent, aspiration catheter or stent assisted by intermediate aspiration catheter, as well as combination of mechanical thrombectomy with intra-arterial thrombolysis
Study NCT06400511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus 0.3% Ophthalmic Ointment
Description: Pimecrolimus 0.3% Ophthalmic Ointment will be applied twice a day to both eyelid margins.
Study NCT06400511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Ointment
Description: Placebo will be applied twice a day to both eyelid margins.
Study NCT06253013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyfe Smartwatch
Description: Passive recording of audio with detection of explosive sounds. When explosive sounds are detected, a 0.5-1 seconds audio clip is recorded, and run through an algorithm to determine whether or not it is a cough.
Study NCT06253013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit Versa 2
Description: Commercial watch with the capability to monitor vital signs including oxygen saturation, respiratory rate and heart rate. Patients will be able to view their data in the FitBit app.
Study NCT06253013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Spirometer
Description: Patients will be able to perform spirometry testing at home. They will be able to view their data, and it will be uploaded to a dashboard for clinicians.
Study NCT06253013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio recording
Description: Patients will be asked to record several sentences which will be analyzed to detect speech patterns that may indicate changes in respiratory conditions.
Study NCT04324619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online interactive learning activities
Description: 1. 3-hour video-storyline-based interactive learning program~2. Micro-learning activities that can be completed on mobile devices (eg, smartphones)
Study NCT04954573 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: infrared-A (wIRA)
Description: Local-water filtered infrared-A (wIRA) irradiation
Study NCT06436625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: outpatient pulmonary rehabilitation
Description: Patients undergo six weeks of an outpatient rehabilitation program in one of the rehabilitation centers (Therme Wien Med, Klinik Pirawarth in Wien).
Study NCT05427006 — intervention group
Intervention type: DEVICE
Intervention: Z5-BL Dental Implants
Description: This is an observational study, collecting data on the use of Z5-BL Dental Implants.
Study NCT05427006 — intervention group
Intervention type: DEVICE
Intervention: Z5-TL Dental Implants
Description: This is an observational study, collecting data on the use of Z5-BL Dental Implants.
Study NCT05856890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepB mAb19
Description: HepB mAb19 is a human mAb of IgG1kappa isotype that specifically binds to the a determinant of the extracellular loop of the HBV surface antigen (HBsAg).
Study NCT05856890 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: Placebo will be normal sterile saline (NaCl 0.9%).
Study NCT06088290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Intravenous Infusion
Study NCT06088290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Short intravenous push or bolus (according to label)
Study NCT06088290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Short intravenous push or bolus (according to label)
Study NCT05507970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV367
Description: Single dose dispersed in sterile water, fasted.
Study NCT05507970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Dose dispersed in sterile water, fasted.
Study NCT05507970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV367 (Fed 440mg)
Description: Single dose dispersed in sterile water with a high fat meal.
Study NCT05507970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV367
Description: Single dose dispersed in sterile water, fasted, administered for 3 consecutive days.
Study NCT05264129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet
Study NCT05264129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral Tablet
Study NCT05507970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose dispersed in sterile water, fasted, administered for 3 consecutive days.
Study NCT05507970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV367 (Fasted 440mg)
Description: Single dose dispersed in sterile water fasted.
Study NCT04748601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qudexy XR
Description: Extended-Release Capsule
Study NCT04748601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Qudexy XR Matching capsules
Study NCT05507021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum DSM 33464, MegaMetalliQ
Description: Pour Lactobacillus Plantarum DSM 33464 sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
Study NCT05507021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pour placebo sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
Study NCT04845659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doptelet Pill
Description: 40 mg or 60 mg Doptelet orally 10-13 days before planned procedure.
Study NCT04845789 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional. Interview would be conducted for data collection.
Study NCT05674786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labyrinth Devices MVI™ Multichannel Vestibular Implant System
Description: Unilateral implantation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System receiver/stimulator including insertion of electrode arrays in the semicircular canal ampullae of the inner ear, followed by motion-modulated prosthetic electrical stimulation.
Study NCT06353542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Software analysis
Description: The tested AI software analyzes the optic disc retinography to determine if the patient is healthy, a glaucoma suspect, or a glaucoma case
Study NCT06353542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ophthalmologist examination
Description: The ophthalmologist (a glaucoma specialist) will analyze the tests and will examine the patient to determine if the patient is healthy, a glaucoma suspect or a glaucoma case
Study NCT05850585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation(FMT)
Description: Subjects will receive FMT capsules (10\^12 Colony-Forming Units(CFU)/capsule) in addition to their usual antipsychotics treatment. Subjects will continue to receive FMT capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
Study NCT05850585 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antipsychotics treatment. Placebo capsules contained the food probiotic Lactobacillus (10\^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
Study NCT05349643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMB-05X
Description: A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
Study NCT05524961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Description: Regularly-timed exposure to 10,000lux bright light therapy for 60minutes a day for six weeks
Study NCT05524961 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated negative ion generator
Description: Regularly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
Study NCT05524961 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactivated negative ion generator
Description: Randomly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
Study NCT05693363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AURA10 Specimen Imager
Description: High-resolution specimen imaging using the AURA10 PET-CT specimen imager during thoracic surgery.
Study NCT04855578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-Hopsital Patient Educational Brochure
Description: The participant's medication list will be identified from the pharmacy database and validated with the participant's best possible medication history taken at time of admission by a pharmacist. Eligibility will be confirmed by the participant's treating medical team with support from the study investigators. Participants who are enrolled during the intervention phase will receive an educational brochure about the risks of chronic gabapentinoid use, and about how to safely discontinue use. The brochure is written using a sixth-grade vocabulary and has been validated in both English and French for comprehension and readability, including for people with mild cognitive impairment.
Study NCT04855578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician Education about Gabapentinoid Prescription
Description: An educational session about the purpose of the study and risks of gabapentinoid prescription will be delivered to physicians (staff and medical residents) on each study unit at both sites during the intervention period. The educational session will include a presentation by the chief of the medical service at the monthly teaching rounds, and an electronic message will be sent to all physicians on the medical service. Physicians will also be presented a brief overview of the educational brochure.
Study NCT05942911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IHL-675A
Description: Combination product containing CBD and HCQ UniGel™ technology by ProCaps®. IHL-675A consists of a solid, film coated HCQ tablet that is contained within a CBD oil solution gel cap. Each IHL-675A gel cap contains 75 mg of CBD and 100 mg HCQ.
Study NCT05942911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: Formulated using UniGel™ technology by ProCaps®. The CBD soft gel capsules contain 75 mg CBD oil solution. These capsules look identical to the IHL-675A UniGel™ capsules, to aid double-blinding
Study NCT05942911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Formulated using UniGel™ technology by ProCaps®. The soft gel capsules each contain a 100 mg HCQ tablet. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
Study NCT05942911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulated using UniGel™ technology by ProCaps®. The soft gel capsules contain the inactive ingredients of the IHL-675A capsules and no active ingredients. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
Study NCT05436314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage
Description: Manual Lymphatic Drainage (MLD) is applied towards the flow direction of lymph vessels with special hand movements. MLD is made with very light, completely painless and rhythmic translational movements of the skin. MLD, by expert and trained physiotherapists (G.K, H.K) in this field. It will be applied with the techniques defined by Dr. Vodder. MLD ( to the neck region, abdominal region, axillary and inguinal lymph nodes) will be applied by following the lymphatic pathways specific to the anterior and posterior trunk, respectively. The treatment session will take approximately 45 minutes. It will be applied 5 days a week during 3 weeks.
Study NCT05436314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical treatment
Description: The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
Study NCT05436314 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Medical treatment
Description: The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
Study NCT05436314 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Manual Lymphatic Drainage
Description: Sham MLD will be administered by MLD-trained physiotherapists (G.K, H.K) with a protocol that is far from techniques that reveal the physiological effects of MLD. Sham application consists of applications that do not follow the lymphatic pathways from distal to proximal to the trunk, neck, and abdominal region, and superficial breathing. The session will take approximately 45 minutes.